Form D · Pharmaceuticals
Syndax Pharmaceuticals Inc
Waltham, MA · CIK 0001395937
Offering snapshot reported Aug 28, 2015 · SEC filing
- Reported sold
- $61.3M Offering amount: $61.3M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 21, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 28, 2015 | Initial | $61,252,462 | No comparison | 19 | SEC filing |
| Jun 15, 2015 | Initial | $23,961,064 | No comparison | 12 | SEC filing |
| Sep 19, 2014 | Initial | $4,947,480 | No comparison | 10 | SEC filing |
| Feb 13, 2014 | Initial | $1,728,471 | No comparison | 3 | SEC filing |
| Feb 13, 2014 | Initial | $1,270,093 | No comparison | 4 | SEC filing |
| Nov 14, 2013 | Initial | $50,000 | No comparison | 1 | SEC filing |
| Aug 30, 2013 | Initial | $31,330,958 | No comparison | 18 | SEC filing |
| Aug 5, 2010 | Initial | $6,006,000 | No comparison | 12 | SEC filing |
| Feb 3, 2010 | Initial | $9,000,000 | No comparison | 13 | SEC filing |
| Apr 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-246643
Source: Form D, filed Aug 28, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Henry Chen | Director |
| Fabrice Egros | Director |
| Fabrice Egros, Ph.D. | Director |
| Luke Evnin, Ph.D. | Director |
| Robert Goodenow, Ph D | Executive |
| Robert Goodenow, Ph.D. | Executive |
| Joanna Horobin, M.D. | Director, Executive |
| Kim Kamdar, Ph D | Director |
| Kim Kamdar, Ph.D | Director |
| Kim Kamdar, Ph.D. | Director |
| Rosina Maar Pavia, M.D. | Director |
| Michael Metzger | Executive |
| Arlene Morris | Director, Executive |
| Briggs Morrison, M.D. | Director, Executive |
| John Pallies | Executive |
| Dennis Podlesak | Director |
| Ivor Royston | Director |
| Ivor Royston, M.D. | Director |
| Richard P Shea | Director |
| George W Sledge, Jr. M.D. | Director |
| George W Sledge, Jr., M.D. | Director |
| Steven St. Peter, M.D. | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
400 Totten Pond Road Suite 110
Waltham, MA, 02451
Waltham, MA, 02451